Plasma cell‐free DNA in ovarian cancer

Abstract

BACKGROUND: Cell‐free DNA reflects both normal and tumor‐derived DNA released into the circulation through cellular necrosis and apoptosis. The authors sought to determine the role of preoperative total plasma cell‐free DNA levels in predicting clinical outcome in patients with ovarian cancer. METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age‐matched controls. The samples were randomly divided into training (n = 144) and validation (n = 144) sets. Quantification of cell‐free DNA was performed using real‐time polymerase chain reaction for β‐globin, and the number of genome equivalents (GE) per milliliter of plasma was determined. Cell‐free DNA was correlated with clinicopathologic parameters. RESULTS: The training and validation sets were similar in terms of demographic features. In the training set, EOC patients had a median preoperative cell‐free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001). Cell‐free DNA >22,000 GE/mL was significantly associated with decreased patient survival (P < .001). After adjusting for other clinical variables, preoperative cell‐free DNA >22,000 GE/mL was an independent predictor (P = .02) for disease‐specific survival. Analysis of the validation set confirmed significantly higher cell‐free DNA levels in EOC (median, 13,672 GE/mL) and that cell‐free DNA >22,000 GE/mL was associated with a 2.83‐fold increased risk of death from disease (P < .001). CONCLUSIONS: Preoperative plasma total cell‐free DNA levels are significantly elevated in patients with EOC. Elevated plasma cell‐free DNA is an independent predictor for death from disease in ovarian cancer. Cancer 2010. © 2010 American Cancer Society.

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

“…Some studies demonstrated that, in cancer patients, higher levels of cfDNA are associated with higher risk of disease recurrence and progression [15, 28, 30, 66, 79–81]. In a study by Diehl et al .…”

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

“…The potential diagnostic, prognostic, and monitoring significance of plasma/serum cfDNA has been clearly demonstrated in breast cancer [6], lung cancer [7], ovarian cancer [8], prostate cancer [9] and gastric cancer [10]. In patients with RCC, Hauser's group demonstrates that levels of circulating cfDNA are increased and mostly originates from tumors [11,12].…”

Circulating cell-free DNAs and miRNAs as promising non-invasive biomarkers for early detection of gastric cancer

“…The amount of circulating cfNAs is influenced by the tumor size and the rate of their clearance [26][27][28]. As the quantifica tion of cfDNA concentrations overlap between healthy individuals and patients with benign and malignant disease [29,30], it is necessary to assess quantitative cfNAs in large cohorts of patients with well-defined clinical parameters. But the remaining high level of cfDNA of the same patient might indicate the presence of residual tumor cells or micro-metastasis in the tumor microenvironment [31].…”